NCT05266196: A Rollover Protocol to Allow for Continued Access to the LSD1 Inhibitor Seclidemstat (SP-2577) |
|
|
| Enrolling by invitation | 1/2 | 10 | US | Seclidemstat, topotecan, cyclophosphamide | Salarius Pharmaceuticals, LLC | Ewing Sarcoma, Myxoid Liposarcoma, Desmoplastic Small Round Cell Tumor, Extraskeletal Myxoid Chondrosarcoma, Angiomatoid Fibrous Histiocytoma, Clear Cell Sarcoma, Myoepithelial Tumor, Low Grade Fibromyxoid Sarcoma, Sclerosing Epithelioid Fibrosarcoma | 12/25 | 12/25 | | |
SALA-002-EW16, NCT03600649: Clinical Trial of SP-2577 (Seclidemstat) in Patients With Relapsed or Refractory Ewing or Ewing-related Sarcomas |
|
|
| Active, not recruiting | 1 | 50 | US | Seclidemstat, LSD1 Inhibitor, SP-2577, Cyclophosphamide, Topotecan | Salarius Pharmaceuticals, LLC, National Pediatric Cancer Foundation | Ewing Sarcoma, Myxoid Liposarcoma, Sarcoma,Soft Tissue, Desmoplastic Small Round Cell Tumor, Extraskeletal Myxoid Chondrosarcoma, Angiomatoid Fibrous Histiocytoma, Clear Cell Sarcoma, Primary Pulmonary Myxoid Sarcoma, Myoepithelial Tumor, Sclerosing Epithelioid Fibrosarcoma, Fibromyxoid Tumor | 09/25 | 12/25 | | |
